Figen Atalay

Prof. Figen Atalay serves as a Professor in the Department of Internal Medicine at Yeditepe University Faculty of Medicine, Istanbul, specializing in hematology-oncology. Her clinical practice and research focus on complex hematologic malignancies, with particular expertise in lymphoma, leukemia, and multiple myeloma management.

Her research portfolio demonstrates deep engagement with therapeutic innovation and clinical challenges in hematology. Key interests include novel agents like belinostat for T-cell lymphomas, ibrutinib for Waldenström macroglobulinemia, and carfilzomib for refractory conditions. She has pioneered investigations into COVID-19's impact on hematologic malignancy patients and contributed significant real-world data on treatment outcomes in Turkish populations.

Analysis of her 15 most recent publications (2018-2024) reveals dominant themes in lymphoma therapeutics, myeloma management, and infectious complications in immunocompromised patients. Her work consistently bridges clinical practice and research through multicenter studies, case reports of rare presentations, and evaluations of novel drug combinations, with strong emphasis on real-world applicability in resource-constrained settings.

Prof. Atalay actively supervises graduate theses as documented in her academic profile, though specific student names and projects are not publicly enumerated. Her scholarly contributions extend to administrative duties within the medical faculty and participation in national hematology networks.